Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · IEX Real-Time Price · USD
34.95
-0.65 (-1.83%)
May 17, 2024, 4:00 PM EDT - Market closed
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $79.41M in the twelve months ending March 31, 2024, with 70.16% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $10.29M with 8.67% year-over-year growth. In the year 2023, Kymera Therapeutics had annual revenue of $78.59M with 67.84% growth.
Revenue (ttm)
$79.41M
Revenue Growth
+70.16%
P/S Ratio
27.16
Revenue / Employee
$424,668
Employees
187
Market Cap
2.16B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
Dec 31, 2019 | 2.93M | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 4.78B |
AMN Healthcare Services | 3.48B |
Teladoc Health | 2.62B |
Amneal Pharmaceuticals | 2.50B |
Integra LifeSciences Holdings | 1.53B |
Amphastar Pharmaceuticals | 676.21M |
STAAR Surgical Company | 326.24M |
ADMA Biologics | 283.18M |
KYMR News
- 4 days ago - Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting - GlobeNewsWire
- 10 days ago - Kymera Therapeutics to Participate in Upcoming May Investor Conferences - GlobeNewsWire
- 16 days ago - Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 23 days ago - Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 - GlobeNewsWire
- 5 weeks ago - Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 2 months ago - Kymera Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 3 months ago - Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update - GlobeNewsWire